Apellis Pharmaceuticals, Inc. — Director's Dealing 2021

Dec 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2021-12-22

Reporting Person: Watson David O. (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-22	Common Stock	M	5174	$13.85	Acquired	104367	Direct
2021-12-22	Common Stock	M	4826	$13.85	Acquired	109193	Direct
2021-12-22	Common Stock	S	5174	$47.716	Disposed	104019	Direct
2021-12-22	Common Stock	M	4715	$14.95	Acquired	108734	Direct
2021-12-22	Common Stock	M	5397	$14.95	Acquired	114131	Direct
2021-12-22	Common Stock	S	5097	$47.855	Disposed	109034	Direct
2021-12-22	Common Stock	S	300	$48.577	Disposed	108734	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (Right to Buy)	$13.85	M	5174	Disposed	2029-02-07	Common Stock (5174)	Direct
2021-12-22	Stock Option (Right to Buy)	$13.85	M	4826	Disposed	2029-02-07	Common Stock (4826)	Direct
2021-12-22	Stock Option (Right to Buy)	$14.95	M	4715	Disposed	2028-02-15	Common Stock (4715)	Direct
2021-12-22	Stock Option (Right to Buy)	$14.95	M	5397	Disposed	2028-02-15	Common Stock (5397)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10000	Indirect

Footnotes

F1: Average Sale Price: Min. $47.34, Max $48.16

F2: Average Sale Price: Min. $47.38, Max $48.25

F3: Average Sale Price: Min. $48.51, Max $48.66

F4: The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.

F5: This option was granted on February 8, 2019 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F6: This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.